For the year ending 2025-12-31, INMB made $50K in revenue. -$46,095K in net income. Net profit margin of -92190.00%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 50 | 14 | ||
| General and administrative | 10,260 | 9,483 | ||
| Research and development | 20,659 | 33,166 | ||
| Impairment of acquired in-process research and development intangible assets | 16,514 | - | ||
| Total operating expenses | 47,433 | 42,649 | ||
| Loss from operations | -47,383 | -42,635 | ||
| Other income (expense), net | - | 553 | ||
| Other income, net | 1,450 | 553 | ||
| Net loss | -45,933 | -42,082 | ||
| Gain (loss) on foreign currency translation | -162 | 224 | ||
| Total comprehensive loss | -46,095 | -41,858 | ||
| Basic EPS | -1.86 | -2.11 | ||
| Diluted EPS | -1.86 | -2.11 | ||
| Basic Average Shares | 24,757,545 | 19,944,304 | ||
| Diluted Average Shares | 24,757,545 | 19,944,304 | ||
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)